Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Analysts

robot
Abstract generation in progress

Dyne Therapeutics (NASDAQ:DYN) has an average “Moderate Buy” rating from seventeen analysts, with a consensus 12-month target price of $35.14. Despite missing Q4 earnings estimates, several analysts have reiterated buy or strong-buy ratings. Insider activity shows a director recently increasing his stake, and institutional ownership remains high.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments